VERTEX PHARMACEUTICALS INCORPORATED for VERTEX PHARMACEUTICALS INCORPORATED
What was lobbied
4 issue areas, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
Issues related to health care and prescription drug pricing in H.R. 5376 - Build Back Better Act, Inflation Reduction Act of 2022 (PL 117-169); H.R. 5801 - HELP Copays Act; H.R. 7506 - New Era of Preventing End-Stage Kidney Disease Act; H.Res. 1330 - Expressing support for the designation of September 2022 as "Sickle Cell Disease Awareness Month".
| Lobbyist | Covered position, as disclosed |
|---|---|
| KWAMME ANDERSON | — |
| SCOTT BARNES | — |
| MATTHEW O SCHUMAKER | — |
| SAMANTHA VENTIMIGLIA | — |
Taxation/Internal Revenue Code TAX
Issues related to corporate and international tax policy and research and development tax credits; Issues related to the Orphan Drug Tax Credit; Issues related to corporate and international tax policy in H.R. 5376 - Build Back Better Act, Inflation Reduction Act of 2022 (PL 117-169).
| Lobbyist | Covered position, as disclosed |
|---|---|
| KWAMME ANDERSON | — |
| SCOTT BARNES | — |
| MATTHEW O SCHUMAKER | — |
| SAMANTHA VENTIMIGLIA | — |
Budget/Appropriations BUD
Issues related to funding for the Food and Drug Administration S. 4661/H.R. 8239 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2023; Issues related to the implementation of the recommendations within The National Academies of Sciences, Engineering, and Medicine (NASEM) report "Addressing Sickle Cell Disease: A Strategic Plan and Blueprint for Action" S. 4659/H.R. 8295 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2023.
| Lobbyist | Covered position, as disclosed |
|---|---|
| KWAMME ANDERSON | — |
| SCOTT BARNES | — |
| MATTHEW O SCHUMAKER | — |
| SAMANTHA VENTIMIGLIA | — |
Medical/Disease Research/Clinical Labs MED
Issues related to FDA regulatory drug review and approval in H.R. 6833, HR 7667 Food and Drug Amendments of 2022, S. 4348 - Food and Drug Administration Safety and Landmark Advancements Act of 2022; Issues related to platform technologies and other FDA-related provisions in S. 3799 - "PREVENT Pandemics Act."
| Lobbyist | Covered position, as disclosed |
|---|---|
| KWAMME ANDERSON | — |
| SCOTT BARNES | — |
| MATTHEW O SCHUMAKER | — |
| SAMANTHA VENTIMIGLIA | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.